Renal Cell Cancer, Recurrent
3 clinical trials · Condition
◉ Watch Renal Cell Cancer, Recurrent
| Record | Firm | Date |
|---|---|---|
| A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) (NCT03634540) | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2018-09-27 |
| Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy (NCT03013946) | AIO-Studien-gGmbH | 2017-01-18 |
Track Renal Cell Cancer, Recurrent automatically
Every clearance here is in the API, with alerts when new ones post.